Harry L A Janssen

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression
    Harry L A Janssen
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Hepatol 39:414-20. 2003
  2. ncbi Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
    Monika van Zonneveld
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Dr. Molewaterplein 40, Room Ca 326, 3015 GD Rotterdam, The Netherlands
    Hepatology 39:804-10. 2004
  3. ncbi Coarse vs. fine needle aspiration biopsy
    Dave Sprengers
    J Hepatol 41:503-4; author reply 504. 2004
  4. ncbi Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
    Bart J Veldt
    Erasmus MC University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands
    Hepatology 47:1856-62. 2008
  5. ncbi Immunology of hepatitis B and hepatitis C virus infections
    Andre Boonstra
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 22:1049-61. 2008
  6. ncbi Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
    Harry L A Janssen
    Department of Gastroenterology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
    Lancet 365:123-9. 2005
  7. ncbi The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection
    Wilhelmus F Leemans
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 44:507-11. 2006
  8. ncbi Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype
    Hajo J Flink
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Am J Gastroenterol 101:297-303. 2006
  9. ncbi Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 22:1093-108. 2008
  10. ncbi Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
    Vincent Rijckborst
    Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 56:1006-11. 2012

Detail Information

Publications77

  1. ncbi Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression
    Harry L A Janssen
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Hepatol 39:414-20. 2003
    ..Thus, the aims of this study were to examine the effects of HBV replication on TRAIL cytotoxicity...
  2. ncbi Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
    Monika van Zonneveld
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Dr. Molewaterplein 40, Room Ca 326, 3015 GD Rotterdam, The Netherlands
    Hepatology 39:804-10. 2004
    ..Our results indicate that after correction for baseline factors, response to IFN therapy increases survival and reduces the risk of developing HCC...
  3. ncbi Coarse vs. fine needle aspiration biopsy
    Dave Sprengers
    J Hepatol 41:503-4; author reply 504. 2004
  4. ncbi Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
    Bart J Veldt
    Erasmus MC University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands
    Hepatology 47:1856-62. 2008
    ..28; 95% CI, 1.35-7.97; P = 0.009). CONCLUSION: For patients with chronic hepatitis C and advanced cirrhosis, diabetes mellitus increases the risk of developing HCC...
  5. ncbi Immunology of hepatitis B and hepatitis C virus infections
    Andre Boonstra
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 22:1049-61. 2008
    ....
  6. ncbi Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
    Harry L A Janssen
    Department of Gastroenterology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
    Lancet 365:123-9. 2005
    ..Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response...
  7. ncbi The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection
    Wilhelmus F Leemans
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 44:507-11. 2006
    ..In our opinion, an analysis of the patient subgroup harbouring an YMDD-mutation should be included in all future studies of pegylated interferon-alpha in chronic hepatitis B...
  8. ncbi Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype
    Hajo J Flink
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Am J Gastroenterol 101:297-303. 2006
    ..Our study indicates that treatment with Peg-interferon alpha-2b is the best therapy to achieve HBsAg clearance in patients with genotype A...
  9. ncbi Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 22:1093-108. 2008
    ..Aiming for sustained response is of particular interest because many HBV-infected patients are in need of antiviral therapy at a young age and may otherwise require indefinite antiviral therapy...
  10. ncbi Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
    Vincent Rijckborst
    Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 56:1006-11. 2012
    ..We aimed at validating this stopping rule in two independent trials...
  11. ncbi Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Gravendijkwal 230, Room Ha 204, Rotterdam, The Netherlands
    J Hepatol 52:493-500. 2010
    ..Entecavir is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients, but data on the efficacy in NA-experienced subjects are limited...
  12. ncbi Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, s Gravendijkwal 230, Room Ha 204, 3015 CE Rotterdam, The Netherlands
    J Hepatol 50:674-83. 2009
    ..We investigated the efficacy of entecavir in lamivudine-experienced and -naïve patients with persistently high HBV DNA during adefovir treatment...
  13. ncbi Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients
    Thjon J Tang
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    J Med Virol 72:215-22. 2004
    ..Response to therapy led to a significant reduction of intrahepatic CD8 T-lymphocytes. Co-localisation of CD8 T-lymphocytes and HBcAg-positive hepatocytes suggests antiviral activity predominantly at the site of maximum HBV replication...
  14. ncbi Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders
    Vincent Rijckborst
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur J Gastroenterol Hepatol 24:1012-9. 2012
    ..Peginterferon (PEG-IFN) is considered as a first-line treatment option for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. We aimed to evaluate the long-term response to PEG-IFN in HBeAg-negative patients...
  15. ncbi Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
    Robert Roomer
    Department of Gastroenterology and Hepatology, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 52:1225-31. 2010
    ..Older patients and patients with poorly controlled diabetes mellitus have a greater risk of developing infections during HCV treatment...
  16. ncbi A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B
    Vincent Rijckborst
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Am J Gastroenterol 105:1762-9. 2010
    ..Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients are at high risk of treatment relapse after any antiviral therapy. Combining peginterferon alpha-2a with ribavirin might improve sustained response rates...
  17. ncbi Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 54:449-54. 2011
    ..We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B virus (HBV) infection during peginterferon (PEG-IFN) and entecavir (ETV) monotherapy...
  18. ncbi The response to TLR ligation of human CD16⁺CD14⁻ monocytes is weakly modulated as a consequence of persistent infection with the hepatitis C virus
    Cheng Peng
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Mol Immunol 48:1505-11. 2011
    ....
  19. ncbi Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine
    Hajo J Flink
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Am J Gastroenterol 101:2523-9. 2006
    ..High serum ALT level at baseline of Peg-IFN alpha2b therapy was the best predictor for response in these patients...
  20. ncbi Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands
    Hepatology 55:1673-83. 2012
    ..MPA's antiviral activity partially depends on IMPDH but also involves stimulation of ISGs, providing a molecular basis for its synergy with IFN-α...
  21. ncbi Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial
    Andrea M Woltman
    Department of Gastroenterology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Antivir Ther 14:809-18. 2009
    ..The present dose-escalating randomized placebo-controlled Phase I/II trial aimed to investigate antiviral activity and safety of alpha-GalCer as a novel class of treatment for chronic hepatitis B patients...
  22. ncbi Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis
    Mark A A Claassen
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, s Gravendijkwal 230, Rotterdam, The Netherlands
    J Hepatol 52:315-21. 2010
    ..However, little is known about Treg present in livers of HCV-infected patients, their association with clinical parameters, and immunopathology resulting in disease progression...
  23. ncbi Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV
    Renate G van der Molen
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 44:907-14. 2006
    ..Our findings provide clues for the reasons why current antiviral therapy does not lead to consistently sustained viral eradication...
  24. ncbi Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent
    Annemiek A van der Eijk
    Department of Hepatology and Gastroenterology, Erasmus MC, University Medical Centre, Room Ca 326, Dr. Molewaterplein 40, 3015 GD Rotterdam, Netherlands
    J Clin Virol 29:92-4. 2004
    ..Our findings show that saliva is a source of HBV DNA.This finding may have implications in selected patients for the infectivity of saliva and offer further insight in the routes of transmission of HBV infection...
  25. ncbi The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells
    Marjoleine L Op den Brouw
    Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
    Virology 393:84-90. 2009
    ..These data suggest that in HBV infected patients, MR-mediated interaction between HBsAg and DC and subsequent impairment of DC predominantly occurs at the main site of infection, the liver...
  26. ncbi Experimental models for hepatitis C viral infection
    Andre Boonstra
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 50:1646-55. 2009
    ..In this article, we give an overview of current models, discuss their limitations, and provide future perspectives for research directed at the prevention and cure of hepatitis C...
  27. ncbi Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus
    Marjoleine L Op den Brouw
    Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
    Immunology 126:280-9. 2009
    ..The direct immune regulatory effect of HBV and circulating HBsAg particles on the function of DC can be considered as part of the mechanism by which HBV escapes immunity...
  28. ncbi Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome
    Harry L A Janssen
    Department of Gastroenterology, Erasmus MC, University Medical Centre, and Virology, Erasmus University, Rotterdam, The Netherlands
    Eur J Gastroenterol Hepatol 16:801-7. 2004
    ..The efficacy of new generation nucleoside analogues should be further elucidated in future studies...
  29. ncbi Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection
    Jan M Vrolijk
    Department of Hepatology and Gastroenterology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Infect Dis 188:1528-32. 2003
    ..Neither peripheral cytokine levels nor HCV-specific T cell reactivity in peripheral blood mononuclear cells showed a relationship to response to therapy...
  30. ncbi The intrahepatic immune response during chronic hepatitis B infection can be monitored by the fine-needle aspiration biopsy technique
    Thjon J Tang
    Department of Gastroenterology and Hepatology, Room L-455, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    FEMS Immunol Med Microbiol 39:69-72. 2003
    ..In conclusion, the FNAB technique is suited to investigate the intrahepatic immune response during chronic hepatitis B infection on a frequent basis...
  31. ncbi Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections
    Bi Sheng Liu
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    J Leukoc Biol 89:981-8. 2011
    ..This suggests that there is no overall increased susceptibility to pathogens but a specific suppression of the functionality of TLR4 signaling pathway in monocytes, which is, at least partly, mediated via IL-10...
  32. ncbi Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies
    Luc J W van der Laan
    Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Virol Methods 142:189-97. 2007
    ..The minimally invasive fine-needle biopsy provides a useful alternative for regular-needle biopsy for monitoring intrahepatic antiviral responses during therapy...
  33. ncbi Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis
    Emile L E de Bruijne
    Department of Hematology, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Thromb Haemost 97:181-5. 2007
    ..In conclusion, genetic variation in the TAFI gene is associated with risk of SVT, suggesting a role for TAFI in the pathogenetic mechanism of SVT...
  34. ncbi Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B
    Jeroen N Stoop
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, s Gravendijkwal 230, Room Ca 326, 3015 CE Rotterdam, The Netherlands
    Virology 361:141-8. 2007
    ..The production of IL10 did not decrease during therapy. In conclusion, adefovir induced viral load reduction results in a decline of circulating Treg together with a partial recovery of the immune response...
  35. ncbi Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C
    Bart J Veldt
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Room Ca 326a, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Hepatol 47:356-65. 2007
    ..The aim of this study was to investigate the safety and the antiviral activity of alpha-galactosylceramide as a novel class of treatment for chronic hepatitis C patients...
  36. ncbi Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans
    Mark A A Claassen
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Virol 85:5323-30. 2011
    ..These findings provide important insight into the dynamics of the immune response to HCV, as well as the effect of therapy on intrahepatic immunity...
  37. ncbi Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B
    Renate G van der Molen
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 40:738-46. 2004
    ..In conclusion, mDC and pDC are functionally impaired in patients with chronic hepatitis B. This might be an important way by which hepatitis B virus evades an adequate immune response, leading to viral persistence and disease chronicity...
  38. ncbi Prospects of RNAi and microRNA-based therapies for hepatitis C
    Qiuwei Pan
    Erasmus MC University Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam 3015 CE, The Netherlands
    Expert Opin Biol Ther 9:713-24. 2009
    ..RNA interference (RNAi) represents a promising new approach to combat viral infections, and recent developments in the field of gene therapy have increased the feasibility of clinical applications...
  39. ncbi Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences
    Jasper H Smalberg
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Arterioscler Thromb Vasc Biol 31:485-93. 2011
    ..These clear differences in underlying risk factors provide leads for further research on the site specificity of venous thrombosis and the development of thrombosis at these distinct sites...
  40. ncbi The Rotterdam Study: 2010 objectives and design update
    Albert Hofman
    Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam The Netherlands
    Eur J Epidemiol 24:553-72. 2009
    ..epib.nl/rotterdamstudy). This article gives the rationale of the study and its design. It also presents a summary of the major findings and an update of the objectives and methods...
  41. ncbi [Non-cirrhotic portal hypertension: rare cause of upper gastrointestinal bleeding]
    Jeoffrey N L Schouten
    afd Maag, Darm en Leverziekten, Erasmus Medisch Centrum Rotterdam, The Netherlands
    Ned Tijdschr Geneeskd 154:A1276. 2010
    ..When portal hypertension occurs in association with patent portal and hepatic veins, and in the absence of liver cirrhosis, NCPH must be considered. The prognosis of this disease is much better than that of cirrhosis...
  42. ncbi New therapeutic opportunities for hepatitis C based on small RNA
    Qiu wei Pan
    Erasmus MC University Medical Centre, Department of Gastroenterology, Room L458, sGravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    World J Gastroenterol 13:4431-6. 2007
    ..In particular, we will focus on the newly defined role of cellular microRNA (miR-122) in viral replication and discuss its potential for HCV molecular therapy...
  43. ncbi Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12
    Bi Sheng Liu
    Liver Unit, Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Eur J Immunol 42:2431-40. 2012
    ..Therefore, type I and III IFNs induce a suboptimal activation of immune cells. These findings are relevant for the development of strategies to further improve IFN-based therapy for patients with multiple sclerosis or viral hepatitis...
  44. ncbi A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients
    Theodora E M S de Vries-Sluijs
    Department of Internal Medicine Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands
    J Infect Dis 203:984-91. 2011
    ..The primary and secondary aims of our study were to investigate the effectiveness and compliance of 2 different vaccination regimen in an HIV-infected population...
  45. ncbi IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNγ receptor expression
    Bi Sheng Liu
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, University Medical Center Rotterdam, s Gravendijkwal 230, Rotterdam, The Netherlands
    Blood 117:2385-95. 2011
    ..Our findings on the differences between IFNα and IL-29 in modulating TLR-induced cytokine production by macrophages may contribute to understanding the role of IFNs in regulating immunity to pathogens...
  46. ncbi Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study
    Jildou Hoekstra
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    J Hepatol 51:696-706. 2009
    ..PNH is an acquired disorder of hematopoietic stem cells, characterized by intravascular hemolysis and venous thrombosis. Testing for this hematological disorder should be considered in all BCS patients...
  47. ncbi Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome
    Sarwa Darwish Murad
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Liver Int 28:249-56. 2008
    ..The clinical outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt (TIPS) for patients with Budd-Chiari syndrome (BCS) is as yet largely unknown...
  48. ncbi Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients
    Annemiek A van der Eijk
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    Eur J Gastroenterol Hepatol 17:1173-9. 2005
    ..The potential infectivity of these body fluids may provide an explanation for the 20% of cases of infection obtained through horizontal transmission for which the origin of infection is yet unknown...
  49. ncbi Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis
    Sarwa Darwish Murad
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Am J Gastroenterol 101:83-90. 2006
    ..These results strongly support a liberal use of anticoagulants, which so far had been widely debated. Alternatively, derivative shunt procedures appear difficult, yet not impossible...
  50. ncbi Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans
    Dave Sprengers
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Hepatol 45:182-9. 2006
    ..Their presence in the liver may suggest a role in the resolution of the infection. Intrahepatic HBV-specific CD8 + T cells remain detectable at high frequencies after HBsAg-seroconversion...
  51. ncbi Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma
    Thjon J Tang
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
    Hum Pathol 37:332-8. 2006
    ..01). In conclusion, patients with HCC have an aberrant composition of the DC population in their hepatic LNs. This may be one of the causes of the inadequate T-cell response against HCC in these patients...
  52. ncbi Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine
    Monika van Zonneveld
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
    Liver Int 26:399-405. 2006
    ..PEG-IFN also improves fibrosis in responders. Addition of lamivudine to PEG-IFN did not further improve the histological outcome...
  53. ncbi Pegylated interferon-alpha2b and lamivudine in hepatitis B e antigen-positive chronic hepatitis B
    Martijn J ter Borg
    Ann Intern Med 143:391; author reply 391-2. 2005
  54. ncbi Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection
    Thjon J Tang
    Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center Rotterdam, Room L-455, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Hepatol 43:45-52. 2005
    ....
  55. ncbi Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs
    Harry L A Janssen
    Hepatology 42:1459; author reply 1459-60. 2005
  56. ncbi Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection
    Jeroen N Stoop
    Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
    Hepatology 41:771-8. 2005
    ..T(reg) have an immunosuppressive effect on HBV-specific T helper cells. The presence of HBV-specific T(reg) could contribute to an inadequate immune response against the virus, leading to chronic infection...
  57. ncbi Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients
    Hans J J van der Vliet
    Department of Internal Medicine, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Clin Immunol 114:183-9. 2005
    ....
  58. ncbi Hepatitis B
    Harry L A Janssen
    N Engl J Med 350:2719-20. 2004
  59. ncbi Low incidence of retinopathy during peginterferon alpha-2b and lamivudine therapy for chronic hepatitis B
    Erik H C J Buster
    J Hepatol 45:160-1; author reply 161-2. 2006
  60. ncbi Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 46:388-94. 2007
    ..Because PEG-IFN therapy results in a high rate of sustained off-therapy response, patients with advanced fibrosis or cirrhosis but compensated liver disease should not be excluded from PEG-IFN treatment...
  61. ncbi Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen
    Dave Sprengers
    Department of Dermatology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastroenterology 134:2132-43. 2008
    ..We here describe a role for V alpha14 iNKT cells in modulating conventional T-cell responses to antigen expressed in liver, using transferrin-mOVA (Tf-mOVA) mice...
  62. ncbi Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastroenterology 135:459-67. 2008
    ....
  63. ncbi Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
    Bart J Veldt
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 147:677-84. 2007
    ..Clinical outcomes of chronic hepatitis C infection in patients with advanced fibrosis include liver failure, hepatocellular carcinoma, and death...
  64. ncbi Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders
    Jilling F Bergmann
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Liver Int 27:1217-25. 2007
    ....
  65. ncbi Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance
    Jinlin Hou
    Institute of Hepatology, University College London, London WC1E 6HX, UK
    J Med Virol 79:1055-63. 2007
    ..The optimal duration of interferon-based therapies in chronic hepatitis B may vary between different HBV genotypes...
  66. ncbi Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response
    Jeroen N Stoop
    Department of Gastroenterology and Hepatology, Erasmus MC Rotterdam, The Netherlands
    Hepatology 46:699-705. 2007
    ..Because chronic HBV patients are known to produce less TNF-alpha, these data implicate an important role for TNF-alpha in the impaired antiviral response in chronic HBV...
  67. ncbi Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response
    Martijn J ter Borg
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, The Netherlands
    Hepatology 44:721-7. 2006
    ..Since there was a considerable response, even in patients with a late or posttreatment decline pattern, prediction of response based on viral decline during the first months of therapy was difficult...
  68. ncbi Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome
    Sarwa Darwish Murad
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 39:500-8. 2004
    ..Our results suggest an improved survival after surgical portosystemic shunting for patients with an intermediate prognosis (class II)...
  69. ncbi Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study
    Manon C W Spaander
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastrointest Endosc 67:821-7. 2008
    ..Esophagogastric variceal bleeding is the most important complication of extrahepatic portal vein thrombosis (EPVT) and is usually treated endoscopically. Little is known about the prognosis of these patients...
  70. ncbi Effectiveness of health-related quality-of-life measurement in clinical practice: a prospective, randomized controlled trial in patients with chronic liver disease and their physicians
    Jolie J Gutteling
    Department of Gastroenterology and Hepatology, Erasmus MC, s Gravendijkwal 230, Rotterdam 3015 CE, The Netherlands
    Qual Life Res 17:195-205. 2008
    ..This study assessed the effectiveness of computerized measurement and feedback of health-related quality of life (HRQoL) in daily clinical practice in patients with chronic liver disease...
  71. ncbi The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
    Jean Jacques Kiladjian
    Assistance Publique Hopitaux de Paris, Hopital Avicenne, Service d Hematologie Clinique, and Université Paris 13, Bobigny, France
    Blood 111:4922-9. 2008
    ..Underlying MPD is associated with severe forms of BCS, but current therapy appears to offset deleterious effects of MPD on the medium-term outcome...
  72. ncbi Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome?
    Sarwa Darwish Murad
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Liver Transpl 13:867-74. 2007
    ..65-0.85). In conclusion, MELD showed a suboptimal discriminative ability to predict survival in BCS. This was explained by the highly variable degree of liver dysfunction and hence clinical outcome in BCS in contrast to ESLD...
  73. ncbi Pseudo-Budd-Chiari Syndrome: decompensated alcoholic liver disease mimicking hepatic venous outflow obstruction
    Harry L A Janssen
    Department of Gastroenterology and Hepatology, Room Ca 326, University Hospital Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Hepatogastroenterology 49:810-2. 2002
    ....
  74. ncbi Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon
    Bart J Veldt
    J Clin Gastroenterol 41:432. 2007
  75. ncbi Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome
    Jasper H Smalberg
    Haematologica 91:1712-3. 2006
    ..In 38% of the BCS patients with MPD another etiological factor was found. JAK2 mutation was present in 41% of the tested BCS patients. Survival was not significantly affected by the presence of MPD...
  76. ncbi JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?
    Harry L A Janssen
    Hepatology 44:1391-3. 2006
  77. ncbi Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
    Ton Lisman
    Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Centre, Utrecht, The Netherlands
    Hepatology 44:53-61. 2006
    ..This phenomenon might compensate for defects in platelet number and function in patients with cirrhosis...